RxDoctor Payments Data

Saima Khurram, MD

Neurology · Canton, GANPI 1710149455

Payments from drug & device makers

$27,527in general payments, 2019–2025

Across 1,161 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Catalyst Pharmaceuticals, Inc.$2K
  • Novartis$1K
  • Biogen$1K
  • Amneal Pharmaceuticals LLC$1K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$1,5516%
  • Food & beverage$25,53593%
  • Education$4402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)183$3,493
UCB, Inc.90$2,223
Catalyst Pharmaceuticals, Inc.7$1,668
Novartis71$1,308
Biogen50$1,233
Amneal Pharmaceuticals LLC57$1,201
Teva Pharmaceuticals USA, Inc.50$996
Neurocrine Biosciences, Inc.46$982
AstraZeneca(2 entities)38$862
EMD Serono, Inc.37$805
Neurelis, Inc.28$803
MDD US Operations, LLC25$726
Lilly USA, LLC28$598
Pfizer25$588
Sunovion Pharmaceuticals Inc.28$557
Johnson & Johnson(2 entities)16$544
Acadia Pharmaceuticals Inc27$536
Lundbeck LLC22$529
Jazz Pharmaceuticals Inc.17$498
SK Life Science, Inc.18$439
Argenx US, Inc.14$416
Adamas Pharmaceuticals, Inc.19$400
Harmony Biosciences LLC17$379
Greenwich Biosciences, Inc.13$368
Supernus Pharmaceuticals, Inc.8$362
Upsher-smith Laboratories LLC19$301
CSL Behring15$296
Acorda Therapeutics, Inc12$248
Sumitomo Pharma America, Inc.10$248
Eisai Inc.11$246
Banner Life Sciences, LLC9$241
Amgen10$233
Axsome Therapeutics, Inc.6$228
Takeda Pharmaceuticals U.S.A., Inc.10$221
Biohaven Pharmaceuticals, Inc.8$208
Avanir Pharmaceuticals, Inc.10$207
Kyowa Kirin, Inc.9$202
Sanofi9$192
Otsuka America Pharmaceutical, Inc.8$168
Grifols USA, LLC8$157
Bristol Myers Squibb6$148
Avion Pharmaceuticals7$148
Octapharma USA, Inc.6$138
Impel Pharmaceuticals Inc.6$126
Bausch Health US, LLC5$112
Medtronic5$110
ANI Pharmaceuticals, Inc.4$107
Biohaven Pharmaceutical Holding Company Ltd.3$80
Aprecia Pharmaceuticals, LLC3$58
Vanda Pharmaceuticals Inc.2$51
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$44
Azurity Pharmaceuticals, Inc.2$44
Globus Medical2$41
Sanofi-aventis U.S. LLC2$39
Assertio Therapeutics, Inc.2$38
Boston Scientific2$34
Merz Pharmaceuticals, LLC1$26
Insightec,inc1$25
Cala Health, Inc.1$25
E.r. Squibb & Sons, L.L.C.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,527 in reported general payments places this provider in the 80th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$252,303
Medicare patients
546
Services billed
12,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5039$1,118,520
PanzygaImmun Glob G(Igg)-Ifas/Glycine20$453,652
Gamunex-CImmune Globul G/Gly/Iga Avg 4654$373,704
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5018$352,000
BotoxOnabotulinumtoxina101$120,658
Nurtec OdtRimegepant Sulfate60$106,413
RytaryCarbidopa/Levodopa73$80,139
Aimovig AutoinjectorErenumab-Aooe62$50,032
BriviactBrivaracetam32$42,383
UbrelvyUbrogepant34$35,141
FycompaPerampanel11$24,701
AptiomEslicarbazepine Acetate16$24,676
Emgality PenGalcanezumab-Gnlm24$20,082
RexultiBrexpiprazole12$17,815
Memantine Hcl493$13,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt, Eliquis$588$570,87897 claims
Grifols USA, LLCGamunex-C$157$373,70454 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$221$352,00018 claims
AbbVieBotox, Ubrelvy$3,493$155,798135 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,201$82,41994 claims
UCB, Inc.Briviact, Neupro$2,223$51,49543 claims
Eisai Inc.Fycompa$246$24,70111 claims
Sunovion Pharmaceuticals Inc.Aptiom$557$24,67616 claims
Otsuka America Pharmaceutical, Inc.Rexulti$168$17,81512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 506 neurology providers in Georgia.

Other neurology in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →